Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.14 -5.0%	$0.62	$0.40 ▼ $2.42	$64.26M	1.14	1.67 million shs	556,919 shs
FENC Adherex Technologies	$8.87 -1.9%	$8.49	$3.96 ▼ $9.42	$251.43M	0.4	69,920 shs	15,975 shs
HUMA Humacyte	$1.58 +3.3%	$2.16	$1.15 ▼ $6.77	$242.31M	1.9	6.30 million shs	3.68 million shs
SOPH SOPHiA GENETICS	$3.31 -0.6%	$3.34	$2.58 ▼ $4.92	$225.04M	1	98,352 shs	58,277 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	-5.00%	+10.68%	+96.55%	+134.66%	-51.28%
FENC Adherex Technologies	-1.88%	+8.57%	+3.86%	+10.46%	+63.05%
HUMA Humacyte	+3.27%	+2.60%	-33.33%	-41.04%	-75.50%
SOPH SOPHiA GENETICS	-0.60%	-3.78%	+1.22%	+11.07%	-12.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALXO ALX Oncology	3.2075 of 5 stars	3.4	1.0	2.8	4.2	1.3
FENC Adherex Technologies	1.9265 of 5 stars	3.5	1.0	2.2	2.5	0.0
HUMA Humacyte	2.1502 of 5 stars	3.5	2.0	1.5	1.7	0.6
SOPH SOPHiA GENETICS	2.7354 of 5 stars	3.5	5.0	2.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.83	Moderate Buy	$3.30	189.47% Upside
FENC Adherex Technologies	3.00	Buy	$13.33	50.32% Upside
HUMA Humacyte	3.00	Buy	$9.75	517.09% Upside
SOPH SOPHiA GENETICS	3.00	Buy	$8.00	141.69% Upside

Current Analyst Ratings Breakdown

Latest ALXO, HUMA, SOPH, and FENC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2025	HUMA Humacyte	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$3.50
8/27/2025	HUMA Humacyte	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$3.50
8/21/2025	FENC Adherex Technologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
8/15/2025	FENC Adherex Technologies	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/15/2025	FENC Adherex Technologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $14.00
8/12/2025	HUMA Humacyte	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.50
8/12/2025	HUMA Humacyte	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
8/11/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/23/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/9/2025	HUMA Humacyte	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$1.20 per share	N/A
FENC Adherex Technologies	$47.54M	5.19	$0.03 per share	279.91	($0.27) per share	-32.85
HUMA Humacyte	$1.57M	159.38	N/A	N/A	$0.03 per share	52.67
SOPH SOPHiA GENETICS	$65.17M	3.43	N/A	N/A	$1.13 per share	2.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$134.85M	-$2.20	N/A	N/A	N/A	N/A	-115.67%	-84.82%	11/6/2025 (Estimated)
FENC Adherex Technologies	-$440K	-$0.42	N/A	N/A	N/A	-35.05%	N/A	-23.92%	11/6/2025 (Estimated)
HUMA Humacyte	-$148.70M	-$0.45	N/A	N/A	N/A	N/A	N/A	-78.26%	11/14/2025 (Estimated)
SOPH SOPHiA GENETICS	-$62.49M	-$0.44	N/A	N/A	N/A	-40.99%	-30.69%	-17.39%	11/4/2025 (Estimated)

Latest ALXO, HUMA, SOPH, and FENC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FENC Adherex Technologies	-$0.06	-$0.11	-$0.05	-$0.11	$9.52 million	$9.76 million
8/12/2025	Q2 2025	ALXO ALX Oncology	-$0.46	-$0.49	-$0.03	-$0.49	N/A	N/A
8/11/2025	Q2 2025	HUMA Humacyte	-$0.15	-$0.24	-$0.09	-$0.24	$0.94 million	$0.30 million
8/5/2025	Q2 2025	SOPH SOPHiA GENETICS	-$0.25	$0.33	+$0.58	$0.33	$17.49 million	$18.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
HUMA Humacyte	N/A	N/A	N/A	N/A	N/A
SOPH SOPHiA GENETICS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.11	4.52	4.52
FENC Adherex Technologies	N/A	4.85	4.59
HUMA Humacyte	2.97	2.45	1.93
SOPH SOPHiA GENETICS	0.62	3.39	3.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
FENC Adherex Technologies	55.51%
HUMA Humacyte	44.71%
SOPH SOPHiA GENETICS	31.59%

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	21.00%
FENC Adherex Technologies	11.76%
HUMA Humacyte	5.10%
SOPH SOPHiA GENETICS	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	53.55 million	42.31 million	Optionable
FENC Adherex Technologies	10	27.81 million	24.54 million	Optionable
HUMA Humacyte	150	158.37 million	150.30 million	Optionable
SOPH SOPHiA GENETICS	520	67.58 million	64.28 million	Not Optionable

ALXO, HUMA, SOPH, and FENC Headlines

Recent News About These Companies

Sophia Genetics Growth Story Clouded By Persistent Losses: Why I'm Choosing To Hold

August 26 at 4:19 AM | seekingalpha.com

SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Down 48.6% in July

August 19, 2025 | marketbeat.com

SOPHiA GENETICS SA: Positive Earnings Call Highlights

August 14, 2025 | theglobeandmail.com

SOPHiA GENETICS SA (NASDAQ:SOPH) Stock Holdings Increased by Federated Hermes Inc.

August 9, 2025 | marketbeat.com

SOPHiA GENETICS Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

August 7, 2025 | finance.yahoo.com

Sophia Genetics SA (SOPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

August 7, 2025 | finance.yahoo.com

SOPHiA GENETICS reaffirms $72M–$76M 2025 revenue guidance as AstraZeneca deal drives BioPharma outlook

August 6, 2025 | msn.com

SOPHiA GENETICS SA (SOPH) Q2 2025 Earnings Call Transcript

August 5, 2025 | seekingalpha.com

SOPHiA GENETICS Reports Financial Results for Mid-2025

August 5, 2025 | tipranks.com

SOPHiA GENETICS Reports Second Quarter 2025 Results

August 5, 2025 | prnewswire.com

SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

August 5, 2025 | prnewswire.com

Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Grows By 123.8%

August 5, 2025 | marketbeat.com

SOPHiA GENETICS (SOPH) Expected to Announce Quarterly Earnings on Tuesday

July 29, 2025 | marketbeat.com

SOPHiA GENETICS to Announce Financial Results for Second Quarter 2025 on August 5, 2025

July 22, 2025 | prnewswire.com

Turning Proof Into Power: Bioz Partners With SOPHiA GENETICS to Enhance Scientific Transparency via Custom Integration

July 15, 2025 | pharmiweb.comP

Sophia Genetics launches podcast to decode data- and AI-driven medical innovation

June 27, 2025 | fiercepharma.comF

An end to an era: Supreme Court won't review IVF mixup ruling

June 26, 2025 | israelnationalnews.comI

Enough hype about AI in health—let’s talk about results

June 12, 2025 | fastcompany.comF

M42, AstraZeneca, and SOPHiA GENETICS launch UAE broad liquid biopsy initiative to transform cancer diagnosis and care

June 3, 2025 | zawya.comZ

M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care

June 3, 2025 | msn.com

M42, partners launch liquid biopsy testing in UAE

June 3, 2025 | tradearabia.comT

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO, HUMA, SOPH, and FENC Company Descriptions

ALX Oncology NASDAQ:ALXO

$1.14 -0.06 (-5.00%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$1.16 +0.02 (+1.32%)

As of 07:10 AM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Adherex Technologies NASDAQ:FENC

$8.87 -0.17 (-1.88%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$8.90 +0.03 (+0.35%)

As of 04:16 AM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Humacyte NASDAQ:HUMA

$1.58 +0.05 (+3.27%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$1.61 +0.03 (+1.90%)

As of 07:00 AM Eastern

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

SOPHiA GENETICS NASDAQ:SOPH

$3.31 -0.02 (-0.60%)

Closing price 08/28/2025 03:59 PM Eastern

Extended Trading

$3.34 +0.04 (+1.06%)

As of 08/28/2025 04:40 PM Eastern

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time